دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
- :
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Strengthening cancer control in Africa gathers momentum
doi : 10.1016/S1470-2045(22)00644-1
Volume 23, Issue 11, November 2022, Page 1343
Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?
Oliver Sartor
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
Masaki Shiota
Chronic convection-enhanced intratumoural delivery of chemotherapy for glioblastoma
Jacob S Young, *Manish K Aghi
What is the best way to treat patients with stage IIA or IIB seminoma?
*Patrizia Giannatempo, Nicola Nicolai
First, do no harm: risk of secondary cancer after breast cancer treatment
*Hope S Rugo, Lisa Singer
Limitations of the radiosensitivity index as a direct prognostic marker
David Robert Grimes
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
*Andrew D J Pearson, Teresa de Rojas, Dominik Karres,Gregory Reaman, Nicole Scobie, Elizabeth Fox,Giovanni Lesa, Franca Ligas, Koen Norga, Karsten Nysom,Alberto Pappo, Brenda Weigel, Susan Weiner, Gilles Vassal
Appropriateness of integrating survival with quality of life and toxicity measures in a single endpoint in ovarian cancer clinical trials
Fiteni Frédéric
Symptomatic melanoma CNS metastases in the TRICOTEL study
Andreas M Schmitt, *James Larkin
Symptomatic melanoma CNS metastases in the TRICOTEL study – Authors' reply
*Reinhard Dummer, Hussein Tawbi
Thoracic CT follow-up after non-small-cell lung cancer resection
*Marjolein A Heuvelmans,Matthijs Oudkerk
Thoracic CT follow-up after non-small-cell lung cancer resection
*Gavitt A Woodard, Daniel J Boffa,Justin D Blasberg
Thoracic CT follow-up after non-small-cell lung cancer resection
Taichiro Goto
Thoracic CT follow-up after non-small-cell lung cancer resection – Authors' reply
*Virginie Westeel, Gérard Zalcman,Arnaud Scherpereel, Bernard Milleron,Fabrice Barlesi
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
*Vivek Tarigopula, Prasant Nayak,Swarnendu Mandal,Manoj Kumar Das, Sambit Tripathy
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
Shuvadeep Ganguly, *Ajay Gogia
Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma
*Tomer Meirson, Victoria Neiman,Michal Sternschuss, Gal Markel,Ian F Tannock
Rezvilutamide for metastatic hormone-sensitive prostate cancer
*Kirti Singh, Swarnendu Mandal,Prasant Nayak, Manoj Das,Sambit Tripathy
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply
*Dingwei Ye, Weijie Gu, Junliang Li
Consolidation in US health care negatively impacts cancer care
Roxanne Nelson
Increase in vaping and e-cigarette use by children in Malaysia
Manjulika Das
WHO urges immediate action to tackle non-communicable diseases
Manjulika Das
Hope for Africa's New Public Health Order to fight cancer
Munyaradzi Makoni
Should chemotherapy-free treatment be offered for advanced oesophageal squamous-cell carcinoma?
Elizabeth C SmythFlorian Lordick
Pursuing excellence in cancer care in Pakistan
Muhammed Aasim Yusuf
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
François-Clément Bidard, Anne-Claire Hardy-Bessard, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Thibault de la Motte Rouge,Renaud Sabatier, Coraline Dubot, Jean-Sébastien Frenel, Jean Marc Ferrero, Sylvain Ladoire, Christelle Levy, Marie-Ange Mouret-Reynier,Alain Lortholary, Julien Grenier, Camille Chakiba, Laetitia Stefani, Jérôme Edouard Plaza, Florian Clatot, Luis Teixeira, Véronique D’Hondt,Hélène Vegas, Olfa Derbel, Claire Garnier-Tixidre, Jean-Luc Canon, Barbara Pistilli, Fabrice André, Laurent Arnould, Anne Pradines, Ivan Bièche,Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, on behalf of the PADA-1 investigators
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial
Georgina V Long*, Jason J Luke*, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo,Jacek Mackiewicz, Vanna Chiarion-Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf,Matteo S Carlino, Peter Mohr, Reinhard Dummer, Jeffrey E Gershenwald, Charles H Yoon, Xi Lawrence Wu, Mizuho Fukunaga-Kalabis,Clemens Krepler, Alexander M M Eggermont, Paolo A Ascierto, on behalf of the KEYNOTE-716 Investigatorsâ€
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
James P Buteau, Andrew J Martin, Louise Emmett, Amir Iravani, Shahneen Sandhu, Anthony M Joshua, Roslyn J Francis, Alison Y Zhang,Andrew M Scott, Sze-Ting Lee, Arun A Azad, Margaret M McJannett, Martin R Stockler, Scott G Williams, Ian D Davis, Michael S Hofman, for theTheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group*
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Axel S Merseburger*, Gerhardt Attard*, Lennart Åström, Vsevolod B Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elżbieta Senkus,Marta López-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial
Eleonora F Spinazzi*, Michael G Argenziano*, Pavan S Upadhyayula*, Matei A Banu*, Justin A Neira, Dominique M O Higgins, Peter B Wu,Brianna Pereira, Aayushi Mahajan, Nelson Humala, Osama Al-Dalahmah, Wenting Zhao, Akshay V Save, Brian J A Gill, Deborah M Boyett,Tamara Marie, Julia L Furnari, Tejaswi D Sudhakar, Sylwia A Stopka, Michael S Regan, Vanessa Catania, Laura Good, Stergios Zacharoulis,Meenu Behl, Petros Petridis, Sachin Jambawalikar, Akiva Mintz, Angela Lignelli, Nathalie Y R Agar, Peter A Sims, Mary R Welch,Andrew B Lassman, Fabio M Iwamoto, Randy S D’Amico†, Jack Grinband†, Peter Canoll†, Jeffrey N Bruceâ€
Evidence-based impact projections of single-dose human papillomavirus vaccination in India: a modelling study
Irene Man, Damien Georges, Tiago M de Carvalho, Lopamudra Ray Saraswati, Prince Bhandari, Ishu Kataria, Mariam Siddiqui, Richard Muwonge,Eric Lucas, Johannes Berkhof, Rengaswamy Sankaranarayanan, Johannes A Bogaards, Partha Basu, Iacopo Baussano
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study
Zev A Wainberg, Peter C Enzinger, Yoon-Koo Kang, Shukui Qin, Kensei Yamaguchi, In-Ho Kim, Anwaar Saeed, Sang Cheul Oh, Jin Li,Haci Mehmet Turk, Alexandra Teixeira, Christophe Borg, Erika Hitre, Adrian A Udrea, Giovanni Gerardo Cardellino, Raquel Guardeño Sanchez,Helen Collins, Siddhartha Mitra, Yingsi Yang, Daniel V T Catenacci, Keun-Wook Lee
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial
Alexandros Papachristofilou, Jens Bedke, Stefanie Hayoz, Ulrich Schratzenstaller, Miklos Pless, Marcus Hentrich, Susanne Krege, Anja Lorch,Daniel-M Aebersold, Paul Martin Putora, Dominik-R Berthold, Deborah Zihler, Friedemann Zengerling, Annette Dieing, Arndt-Christian Mueller,Corinne Schaer, Christine Biaggi, Silke Gillessen, Richard Cathomas
Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study
Lene H S Veiga, Jacqueline B Vo, Rochelle E Curtis, Matthew M Mille, Choonsik Lee, Cody Ramin, Clara Bodelon, Erin J Aiello Bowles,Diana S M Buist, Sheila Weinmann, Heather Spencer Feigelson, Gretchen L Gierach, Amy Berrington de Gonzalez
Association of the interaction between mosaic chromosomal alterations and polygenic risk score with the risk of lung cancer: an array-based case-control association and prospective cohort study
Na Qin*, Cheng Wang*†, Congcong Chen*, Liu Yang*, Su Liu, Jun Xiang, Yuan Xie, Shuang Liang, Jun Zhou, Xianfeng Xu, Xiaoyu Zhao, Meng Zhu,Guangfu Jin, Hongxia Ma, Juncheng Dai, Zhibin Hu†, Hongbing Shenâ€
Progress and remaining challenges for cancer control in the Gulf Cooperation Council
Samar Alhomoud, Saleh Al-Othman, Amal Al-Madouj, Mohamad Al Homsi, Khaled AlSaleh, Khalid Balaraj, Adil Alajmi, Partha Basu,Ali Al-Zahrani
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries
Ellen Nolte, Melanie Morris, Susan Landon, Martin McKee, Maureen Seguin, John Butler, Mark Lawler
Accelerating the integration of China into the global development of innovative anticancer drugs
Huiyao Huang*, Dawei Wu*, Huilei Miao*, Yu Tang, Chengcheng Liu, Hong Fang, Xinyu Meng, Shuhang Wang, Qi Zhu, Xin Wang, Jingting Du,Zhimin Yang, Ning Li, Binghe Xu, Jie He
Metastatic epithelioid aortic angiosarcoma
Wiaam Elkhatib, Razvan Chirila
